Literature DB >> 8579116

Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas.

S Kauppila1, J Saarela, F Stenbäck, J Risteli, A Kauppila, L Risteli.   

Abstract

Malignant ovarian tumors induce a strong fibro-proliferative reaction characterized by the active production of type I and type III procollagen both locally in the ovary as well as more remotely in the peritoneal cavity. Our purpose was to determine the origin of the increased collagen production observed in serous ovarian tumors with different histological grades of malignancy, ie, whether the malignant cells or the stromal fibroblasts are responsible for the synthesis of collagen fibers. We visualized the mRNAs corresponding to the pro alpha 1(I) and pro alpha 2(I) chains of type I procollagen and the pro alpha 1(III) chain of type III procollagen by in situ hybridization. Strong signals for both chains of type I procollagen were seen in stromal fibroblasts next to tumor cell islets, whereas the reaction was weak or absent near benign ovarian cysts. In poorly differentiated tumors, the signals were particularly abundant and occasionally also seen in the neoplastic cells themselves. Type III procollagen mRNA expression was similar, although somewhat less distinct. These findings indicate that the production of interstitial procollagens is related to the degree of malignancy and neoplastic activity of tumors. The formation of collagen in well differentiated ovarian tumors is a function of stromal fibroblasts, whereas in poorly differentiated tumors, aberrant expression of one or several chains of type I and type III procollagens in the neoplastic cells is also likely to take place.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8579116      PMCID: PMC1861689     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

Review 1.  Cancer invasion and metastases.

Authors:  L A Liotta; E Kohn
Journal:  JAMA       Date:  1990-02-23       Impact factor: 56.272

2.  Aminoterminal propeptide of type-III procollagen in serum--an indicator of clinical behavior of advanced ovarian carcinoma?

Authors:  L Risteli; A Kauppila; U M Mäkilä; J Risteli
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

3.  Human pro alpha 1(I) collagen: cDNA sequence for the C-propeptide domain.

Authors:  J K Mäkelä; M Raassina; A Virta; E Vuorio
Journal:  Nucleic Acids Res       Date:  1988-01-11       Impact factor: 16.971

4.  Structure of a full-length cDNA clone for the prepro alpha 2(I) chain of human type I procollagen. Comparison with the chicken gene confirms unusual patterns of gene conservation.

Authors:  H Kuivaniemi; G Tromp; M L Chu; D J Prockop
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

Review 5.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.

Authors:  H F Dvorak
Journal:  N Engl J Med       Date:  1986-12-25       Impact factor: 91.245

Review 6.  Connective tissue as an active participant in the process of malignant growth.

Authors:  A Van den Hooff
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

7.  Coordinated regulation of type I and type III collagen production and mRNA levels of pro alpha 1(I) and pro alpha 2(I) collagen in cultured morphea fibroblasts.

Authors:  T Vuorio; J K Mäkelä; V M Kähäri; E Vuorio
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

8.  Structure of a cDNA for the pro alpha 2 chain of human type I procollagen. Comparison with chick cDNA for pro alpha 2(I) identifies structurally conserved features of the protein and the gene.

Authors:  M P Bernard; J C Myers; M L Chu; F Ramirez; E F Eikenberry; D J Prockop
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

9.  Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.

Authors:  A Kauppila; U Puistola; J Risteli; L Risteli
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

10.  Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms.

Authors:  G G Zhu; L Risteli; M Mäkinen; J Risteli; A Kauppila; F Stenbäck
Journal:  Cancer       Date:  1995-02-15       Impact factor: 6.860

View more
  8 in total

1.  Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.

Authors:  Sharareh Siamakpour-Reihani; Kouros Owzar; Chen Jiang; Taylor Turner; Yiwen Deng; Sarah M Bean; Janet K Horton; Andrew Berchuck; Jeffrey R Marks; Mark W Dewhirst; Angeles Alvarez Secord
Journal:  Gynecol Oncol       Date:  2015-08-07       Impact factor: 5.482

2.  Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo.

Authors:  S Kauppila; M K Bode; F Stenbäck; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

Review 3.  The role of the tumor stroma in ovarian cancer.

Authors:  Ben Davidson; Claes G Trope; Reuven Reich
Journal:  Front Oncol       Date:  2014-05-13       Impact factor: 6.244

4.  MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases.

Authors:  Juliana Pereira Lopes Gonçalves; Christine Bollwein; Anna Melissa Schlitter; Mark Kriegsmann; Anne Jacob; Wilko Weichert; Kristina Schwamborn
Journal:  Molecules       Date:  2022-07-27       Impact factor: 4.927

5.  Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.

Authors:  M Santala; J Risteli; L Risteli; U Puistola; B M Kacinski; E R Stanley; A Kauppila
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

6.  Comparative proteome analysis of human epithelial ovarian cancer.

Authors:  Jean-Philippe Gagné; Chantal Ethier; Pierre Gagné; Geneviève Mercier; Marie-Eve Bonicalzi; Anne-Marie Mes-Masson; Arnaud Droit; Eric Winstall; Maxim Isabelle; Guy G Poirier
Journal:  Proteome Sci       Date:  2007-09-24       Impact factor: 2.480

7.  miR-29b enhances prostate cancer cell invasion independently of MMP-2 expression.

Authors:  Renato F Ivanovic; Nayara I Viana; Denis R Morais; Iran A Silva; Katia R Leite; José Pontes-Junior; Gustavo Inoue; William C Nahas; Miguel Srougi; Sabrina T Reis
Journal:  Cancer Cell Int       Date:  2018-02-05       Impact factor: 5.722

8.  Exploring prognostic genes in ovarian cancer stage-related coexpression network modules.

Authors:  Lili Yang; Jili Jing; Liqun Sun; Ying Yue
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.